European Journal of Surgical Oncology 1998; 24: 614–630

ABSTRACTS

British Association of Surgical Oncology
Silver Jubilee Scientific Meeting

held at The Royal College of Surgeons of England, 35–42 Lincoln’s Inn Fields, London, UK on 26 and 27 November 1998

Abstracts of members’ papers

Plenary Session I

1. Advanced breast biopsy instrumentation—accurate diagnosis of impalpable mammographic abnormalities

The Academic Surgical Unit, University of Hull, Castle Hill Hospital, Hull, UK

Introduction: Accurate pre-operative diagnosis of mammographic abnormalities is essential through difficult to achieve, necessitating open surgical diagnostic biopsy in 4035 cases in the UK Breast Screening Programme 1997-98. We have prospectively assessed a multidisciplinary minimally invasive approach to diagnosis of 232 such lesions assessed in our unit over the past year.

Methods: Unit policy was that all patients had initial clinical and ultrasonographic assessment. Initial stereotactic or ultrasound (U/S) guided fine needle aspiration cytology (FNA) was performed by a radiologist and stained using H&E or Papanicloau stains. Further investigation, if required, involved prone table core biopsy or advanced breast biopsy instrumentation (ABBI) excision.

Results: A peritumoural infiltrate of TILs was associated with an improved survival (P=0.01). High scores of Fas ligand in the tumour cells were associated with low scores of CD8+ lymphocytes around the turnout, and vice versa (P=0.03). There was a trend for lower numbers of intratumoural TILs in tumours with increased expression of Fas ligand in the cancer cells. Tumours with prominent staining for Fas ligand tended to have a poorer survival (P=0.08).

Conclusion: The results from this study provide evidence to support the concept of a “Fas counter attack” in vivo in the tumours of patients with colorectal cancer.

2. Evidence for the Fas “counter attack” by tumour cells in patients with colorectal cancer

I. C. Smith, E. Arbuckle, O. Langlois, O. Erenin, S. D. Hays
Surgical Nutrition and Metabolism Unit, Departments of Surgery and Pathology, University of Aberdeen, Aberdeen, UK

Background: The Fas receptor (CD95) is expressed by lymphocytes and other cells including colorectal cancer cells. It has been shown that a peritumoural infiltrate of lymphocytes is associated with a good prognosis in colorectal carcinoma. One proposed mechanism is that cytotoxic T lymphocytes (CTLs) expressing Fas ligand activate Fas receptors on the tumour cells, which then induces apoptosis. However, in vitro studies have suggested that tumours may be able to mount a “counter attack” against CTLs by downregulating the CTL Fas pathway and enhancing their own Fas ligand, thereby inducing apoptosis in the tumour infiltrating lymphocytes (TILs). However, the relevance of this mechanism in human cancers in vivo is not known.

Methods: Colorectal cancers from 94 patients treated for colorectal cancer were examined. Immunostaining was performed for CD8+ (CTLs) cells and Fas ligand using a standard technique with appropriate positive and negative controls. Histological sections were scored by two observers using a standard scoring system assessing the degree of expression for each of these (0—absent/very weak, to 3—strong). Possible prognostic factors were examined using univariate analysis.

Results: A peritumoural infiltrate of TILs was associated with an improved survival (P=0.01). High scores of Fas ligand in the tumour cells were associated with low scores of CD8+ lymphocytes around the tumour, and vice versa (P=0.03). There was a trend for lower numbers of intratumoural TILs in tumours with increased expression of Fas ligand in the cancer cells. Tumours with prominent staining for Fas ligand tended to have a poorer survival (P=0.08).

Conclusion: The results from this study provide evidence to support the concept of a “Fas counter attack” in vivo in the tumours of patients with colorectal cancer.

3. Characterization of the oestrogen-responsive finger protein in benign and malignant human breast

S. D. Thomson, S. Ali, R. C. Coombes
CRC Laboratories, Charing Cross Hospital, London, UK

Up to 70% of breast cancers respond to anti-oestrogen therapy, but almost all eventually become resistant and progress. A clearer understanding of the involved pathways could suggest new treatment options. The recently-discovered oestrogen-responsive finger protein (Efp) (Inoue S. et al., Proc Natl Acad Sci USA 1993; 90: 11117–21) contains a RING finger domain and may be able to mount a “counter attack” in vivo in the tumours of patients with colorectal cancer.
who have multifocal disease not evident on standard triple assessment. MRI of the breast should be used for the pre-operative planning of surgery for primary breast cancer.

14. Sentinel node biopsy and axillary node sampling—how they compare

Professional Unit of Surgery, City Hospital, Nottingham, UK

Sentinel node biopsy (SNB) is proposed as a minimally invasive method of staging the axilla. Axillary node sampling (ANS) is an established minimally invasive staging procedure of known efficacy. This study was designed to allow a comparison between SNB and ANS.

Sixty-one patients with operable breast cancer were pre-operatively injected with 111In-labelled colloid (Nanocoll, Amersham Healthcare) immediately adjacent to the tumour. Median interval between injection and surgery was 4 h (1-18). At operation a standard four-node ANS was performed following staging the axilla. Axillary node sampling (ANS) is an established minimally invasive staging procedure of known efficacy. This study was designed to allow a comparison between SNB and ANS.

In all cases where the SN was not part of the ANS in 72% of cases. In all cases where the SN was not part of the ANS the nodes were negative. One SN excised in a patient with a positive ANS was falsely negative. This study demonstrates that the sentinel node is frequently missed by ANS. However, when compared with SNB, no patient was understaged by ANS while one patient was understaged by SNB.

15. A new method of localizing impalpable breast lesions

M. E. L. Gamma1, K. Steppi, A. G. Paterson2, G. Vivian3, D. Christensen4, B. Elliot4, J. Hope4
1Department of Surgery, St. Michael's Hospital, Hayle, 2Mermaid Breast Centre, 3Department of Nuclear Medicine and 4Department of Pathology, BCTH, Truro, Cornwall, UK

Background: Accurate localization of suspicious non-palpable breast lesions is essential prior to excision biopsy. Several techniques are available for localization, the most commonly used method being guide wire introduction under mammographic or ultrasonic control. Disadvantages of this method include displacement, migration, breakage and difficulty in placing the wire (anatomy). Dissection to follow the wire can sometimes be difficult, especially if the skin entry site is far from the lesion. The aim of this study is to localize and remove suspicious impalpable breast lesions using Tcm99 and a handheld gamma probe.

Patients and methods: Seventeen patients with screen-detected impalpable lesions were studied. On the morning of the operation 3.6 MBq of Tcm99 labelled on human albumin were injected into the lesion under ultrasonic or mammographic control. At surgery the hand-held gamma probe (EURO PROBE) was used to detect the area of maximum radioactivity, corresponding to the lesion. This permitted placement of the skin incision directly over it. The excised lesion was then rechecked with the probe to confirm its successful removal and the cavity checked for any residual activity to assure completeness of excision. Specimen mammography was performed followed by routine histological examination.

Results: All 17 lesions were successfully localized and removed (100%). Histology: ductal carcinoma in situ (5), invasive carcinoma (7) and benign (5).

Conclusions: We found this new method of localization for excision biopsy of non-palpable breast lesions easier, less time consuming and avoiding inherent problems associated with the guide wire method.

16. Use of digital imaging improves upright stereotactic core biopsy of suspicious microcalcifications

Breast Screening Training Unit, Nottingham City Hospital, Hucknall Road, Nottingham, NG3 1PB, UK

This study assesses whether the addition of digital check images aids the accurate performance of core biopsy of suspicious microcalcifications using upright stereotactic equipment.

We have compared results from a consecutive series of 104 upright stereotactic 14-gauge core biopsies performed prior to the acquisition of a new digital add-on device with a series of 34 biopsies carried out using the digital facility. The biopsies were performed by experienced radiologists working in our unit over a 32-month period from January 1996, with the digitally aided procedures performed from November 1997 onwards. In all cases specimen radiography was performed and analysed for the presence of radiographic calcifications in the core specimens. Pathological correlation was then carried out with needle histology categorized as normal, benign, atypical ductal hyperplasia (ADH), suspicious of ductal carcinoma in situ (DCIS), DCIS or invasive carcinoma. Biopsy was repeated if no calcifications were obtained and core histology was not clearly malignant. Definitive surgical histology was also documented for all cases in which a diagnostic or therapeutic surgical excision was performed.

The use of digital add-on equipment increased the radiographic calcification retrieval rate from 57/104 (55%) to 28/34 (82%), P<0.005. The complete sensitivity in DCIS cases rose from 15/29 (52%) to 11/11 (100%), P<0.005. The absolute sensitivity in DCIS cases before digital imaging was 10/29 (34%) and 7/11 (64%) using digital check films (not significant).

We have concluded, therefore, that digital equipment greatly facilitates performance of upright stereotactic core biopsy for suspicious microcalcifications, giving a significantly increased success rate in accurately targeting and obtaining calcifications and, more importantly, a marked improvement in the complete sensitivity for DCIS.

17. Breast reconstruction: comparing five different methods of breast volume measurement

N. Bulstrode1, E. Bellamy2, S. Shrotriya
1Breast Surgery Unit and 2Department of Radiology, Ashford Hospital, Ashford, Middlesex, TW15 3AA, UK

Breast surgery has become more conservative with regard to the extent of excision due to the improvement in adjuvant therapy. There has also been a great improvement in techniques for reconstruction. For a successful procedure in terms of cosmesis an accurate and reliable figure for breast volume is required. This will enable improved planning and choice of procedure leading to better operative result. There have been numerous methods of breast volume measurement none of which have been compared to each other.

We compared five methods of breast volume assessment: (1) mammography, which has previously been compared to mastectomy specimens; (2) thermoplastic moulding; (3) magnetic resonance imaging; (4) Archimedes principle; (5) anatomical measurements. We also assessed the acceptability of each method to both the patient and clinician. Measurements were performed on 10 women, therefore 20 breasts.

We were able to calculate prediction equations between volume measurements obtained from mammography by the other four methods. (1) MR, 368 + (0.73 MRI) [± 69]. (2) Thermoplastic moulding, 132 + (1.46 thermoplastic moulding) [± 442]. (3) Anatomical measurements, 168 + (1.55 anatomical measurements) [± 437]. (4) Archimedes principle, 359 + (0.6 Archimedes principle) [± 152].

If a mammogram has been performed this is the method of choice. If due to age or lack of pathology no mammogram has been performed then thermoplastic moulding and anatomical measurements should be used. MRI is presently too expensive. Water displacement was the least reproducible and therefore we have advised against its use.

18. Interval cancers—are they different from symptomatic breast cancers?

H. Y. Chan, A. L. Harris, P. Jane Clarke, M. J. Greenall
Oxford Radcliffe Hospitals, Oxford, UK

Introduction: Interval cancers provide cause for concern for the NHS breast screening programme (NHSBSP). Higher than anticipated rates of interval tumours have been reported by the NHSBSP; in addition, there are conflicting views regarding the survival of women with interval tumours. There have been few data to date reporting the survival of these women in the NHSBSP. This study analyses the tumour characteristics and survival of women diagnosed with interval cancer and compares these to a control group of women with symptomatic cancers.

Patients and methods: 107 women aged 50–67 years were diagnosed with an interval cancer between 1991 and 1996. These data were compared to a control group of 337 women of similar age who were treated for a symptomatic cancer in the same centre between 1987 and 1993. Adjuvant treatment was given according to standard local protocols. All data were collected prospectively onto computerized databases. Differences in tumour...
characteristics were analysed by Mann Whitney U and chi-squared tests and differences in survival by the log-rank test.

**Results:** Interval cancers were similar to control tumours for tumour size (mean diameter 25.9 vs. 26.7 mm; P = 0.10, Mann Whitney U), tumour grade (mean 2.2 vs. 2.3; P = 0.45) and number of positive nodes (mean 1.86 vs. 1.82; P = 0.54). ER positivity was similar in both groups (64.4% vs. 53.1%; \( \chi^2 = 3.27; df = 1; P = 0.071 \)). Breast conservation was more commonly performed for interval tumours (84.1% vs. 64.3%; \( \chi^2 = 13.39; df = 1; P = 0.0002 \)). The overall survival of both groups was similar (log-rank test \( \chi^2 = 1.91; df = 1; P = 0.17 \)).

**Conclusions:** These data suggest that interval cancers are similar to symptomatic tumours both in terms of their pathological features and outcome. This supports the recent report suggesting that survival is similar between the two groups. Hence, in the UK, there is little evidence to substantiate the concern that interval cancers fare worse than the symptomatic controls.

Reference

19. Randomized trial of the effect of hyperbaric oxygen on response to primary chemotherapy for breast cancer

Surgical Nutrition and Metabolism Unit, Departments of Surgery, Radiology, Oncology and the Hyperbaric Centre, University of Aberdeen, UK

**Introduction:** Hyperbaric oxygen (HBO) has been shown to potentiate the effects of chemotherapy in animal tumour models. However, the effects of HBO on human cancers in vivo have been poorly investigated and, to date, no randomized trials have been reported. The aim of this study was to investigate the effects of HBO therapy in potentiating the effects of chemotherapy in patients with breast cancer.

**Patients and methods:** Thirty were randomized to the study group (n = 15), receiving either 10 treatments of HBO therapy at 2.4 Atmospheres absolute, 100% oxygen, (in an attempt to induce tumour neovascularature) or to the control group (n = 15) who did not receive HBO. Patients then were treated with a standard anthracycline-based primary chemotherapy regimen given over 18 weeks. Tumour response was assessed by histological examination of the resected breast tissue following completion of primary chemotherapy and graded according to a previously validated scale (1 = no response to 5 = complete response).

**Response:** The mean age of the patients was 55 years, ranging from 30 to 70 years. All patients successfully completed the study protocol and tolerated the HBO therapy without problems. Pathological responses were graded as follows:

<table>
<thead>
<tr>
<th>Path response</th>
<th>HBO</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**Conclusions:** Hyperbaric oxygen treatment prior to primary chemotherapy was well tolerated by the patients without complications. However, the use of HBO does not result in a significantly increased pathological response to primary chemotherapy.

20. Radiosurgery: an innovative method of treatment for early breast cancer

Department of Surgery, Radiation Oncology and Medical Physics, University College London, Norfolk & Norwich Hospital, UK, and Photoelectron Corporation, Lexington, MA, USA

The local treatment of breast cancer appears to have dramatically changed in the last 30 years. However, although the outcome is 'conservative' the intention is 'radical' with the radiotherapy fields encompassing virtually all of the tissues previously excised by radical mastectomy. We propose that this approach be changed. In large studies of breast conservative therapy more than 90% of early breast recurrences have been found to occur at the site of the original primary tumour, whether or not radiotherapy is given and whether or not the margins are involved. This is in spite of the fact that, when mastectomy specimens are examined by detailed radiological-histological correlational methods, small additional invasive or in situ cancer foci are found in over 60% of patients, with 80% of these located remote from the index quadrant. Hence it appears that these additional cancers do not in general give rise to local recurrence which more probably develops from the cells that surround the primary tumour, which may be genotypically abnormal although morphologically 'clear'.

We describe here a pilot study using a novel method of radiotherapy to deliver therapeutic radiation to the tissues around the primary tumour immediately following excision, with a degree of precision impossible with an external beam. The Photon Radiosurgery System (PRS) is a simple and ingenious device which in essence is a miniature electron-beam driven x-ray source which provides a point source of low energy x-rays at the tip of a 3.2-mm diameter tube. The radiation source is surrounded by a conical sheath with a sphere at the tip, enabling delivery of a uniform dose of radiation to a prescribed depth. Since the radiation consists of soft x-rays, the beam is rapidly attenuated to reduce the dose to more distant tissue. Depending upon the size of the surgical cavity, various sizes of applicator spheres are available and for each size, the radiation received is proportional to the time the machine is switched on and left in situ. A dose of about 3Gy can be delivered in about 30 min at 1 cm from the margins of the cavity after wide local excision of the tumour. With this elegant approach the pliable breast tissue around the cavity of surgical excision wraps around the radiotherapy source, i.e. the target is 'conformed' to the source, rather than vice versa.

After completion of this pilot, we propose to undertake a phase II randomized trial comparing conventional radiotherapy with PRS alone, with a potential saving of 6 weeks of external beam radiotherapy time for both the patient and the overstretched resources of radiotherapy departments.

21. Screening of family history patients—what constitutes high risk?

K. Hogben, J. Viggers, J. Daviey, G. Curling, N. Birch, G. Walsh, J. A. McKenna, T. Powles, N. Sacks, G. Gal
Breast Diagnostic Unit, Royal Marsden Hospital, London, UK

**Aims:** Women with a family history of breast cancer attend specialist clinics for high-risk screening. There are currently no uniform criteria for what constitutes increased risk, leading to considerable variation in local practice. A limiting factor of previous studies has been the high number of patients who did not develop cancer, affecting the calculation of incidence data.

**Methods:** This project is a cross-sectional study of breast cancer detected in a high-risk clinic to evaluate the relative risk of cancer from family history. Women were categorized into lifelong risk of between 1:12 and 1:8 (low risk) and greater than 1:8 (high risk), based on Claus predictive tables. 1677 women attenders with a family history of breast cancer between September 1993 and August 1994 with a mean follow-up of 110 (range 12–357) months were reviewed in this retrospective study. Screening consisted of annual review and mammography. Within each group, breast tumour variables were obtained and compared with data of family history risk.

**Results:**

<table>
<thead>
<tr>
<th>Path response</th>
<th>HBO</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**Conclusions:** These data suggest that interval cancers are similar to control tumours for tumour size (mean diameter 26.7 mm; P = 0.10, Mann Whitney U), tumour grade (mean 2.2 vs. 2.3; P = 0.45) and number of positive nodes (mean 1.86 vs. 1.82; P = 0.54). ER positivity was similar in both groups (64.4% vs. 53.1%; \( \chi^2 = 3.27; df = 1; P = 0.071 \)). Breast conservation was more commonly performed for interval tumours (84.1% vs. 64.3%; \( \chi^2 = 13.39; df = 1; P = 0.0002 \)). The overall survival of both groups was similar (log-rank test \( \chi^2 = 1.91; df = 1; P = 0.17 \)).

**Conclusions:** The incidence of breast cancer in the low-risk group is only slightly higher than that of the general population. Screening patients with a low risk may be of limited value. The median age of diagnosis was 43 (26–57) years. The effect of early diagnosis on survival is unknown and will require a large prospective study.